Vericel (VCEL) Stock Price, News & Analysis

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings or view top-rated stocks.

6 brokers have issued 12 month target prices for Vericel's stock. Their VCEL share price targets range from $39.00 to $54.00. On average, they predict the company's stock price to reach $46.40 in the next twelve months. This suggests that the stock has a possible downside of 2.4%.
View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts.

Vericel's stock was trading at $35.61 at the start of the year. Since then, VCEL stock has increased by 33.4% and is now trading at $47.52.
View the best growth stocks for 2024 here.

Vericel saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,390,000 shares, an increase of 85.2% from the March 15th total of 2,370,000 shares. Based on an average daily trading volume, of 536,800 shares, the short-interest ratio is currently 8.2 days.
View Vericel's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VCEL earnings forecast.

Vericel Co. (NASDAQ:VCEL) posted its earnings results on Thursday, February, 29th. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.08. The biotechnology company had revenue of $65 million for the quarter, compared to analysts' expectations of $64.28 million. Vericel had a negative net margin of 1.61% and a negative trailing twelve-month return on equity of 1.55%. The business's revenue for the quarter was up 23.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.12 earnings per share.

ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Syntax Stratified SmallCap ETF (SSLY).

Vericel issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $237.0 million-$241.0 million, compared to the consensus revenue estimate of $240.8 million.

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel's stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (1.73%), Los Angeles Capital Management LLC (0.06%), Park Avenue Securities LLC (0.01%), Juncture Wealth Strategies LLC (0.01%) and MCF Advisors LLC (0.00%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends.

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.